Organisation paid for research Program year 2025 Source: CMS Open Payments

Coastal Pediatric Associates

Neither a doctor nor a teaching hospital

Research payments

$501,592

87 payments

Through program year 2025, Coastal Pediatric Associates is reported as receiving $501,592 in research payments, across 87 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $987 1
2024 Research $55,057 9
2023 Research $77,148 9
2022 Research $76,472 20
2020 Research $207,285 20
2019 Research $84,642 28

Breakdown

Who paid Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $209,003 30 payments
  2. AstraZeneca Pharmaceuticals LP $66,281 1 payment
  3. Incyte Corporation $56,934 18 payments
  4. Covidien LP $52,950 5 payments
  5. Pfizer Inc. $32,901 14 payments
  6. AbbVie, Inc. $27,657 6 payments
  7. Sanofi Pasteur Inc. $25,000 1 payment
  8. Regeneron Pharmaceuticals, Inc. $14,050 5 payments
  9. AstraZeneca UK Limited $11,250 1 payment
  10. Allergan Inc. $3,066 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP) $163,254 14 payments
  2. Open-label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ? 29 Weeks Gestational Age to < 18 Years $77,531 2 payments
  3. BiZact Pediatric $52,950 5 payments
  4. A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $48,977 10 payments
  5. A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents $45,749 16 payments
  6. A Phase 2 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Conjugate Vaccines in Healthy Infants $32,901 14 payments
  7. A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 4-arm study to investigate the mixed vaccination schedules of a 21-valent pneumococcal conjugate vaccine and a 20-valent pneumococcal conjugate vaccine in healthy infants and toddlers $25,000 1 payment
  8. A Phase 2A, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous or Intramuscular Anti- Spike(s) SARS-COV-2 Monoclonal Antibodies (Casirivimab and Imdevimab) in High-Risk Pediatric Subjects Under 12 Years of Age $14,050 5 payments
  9. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $11,341 2 payments
  10. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $7,968 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record